We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philip Morris' Q3 Earnings Coming Up: Here's What You Should Know
Read MoreHide Full Article
Philip Morris International Inc. (PM - Free Report) is likely to register top and bottom-line growth when it reports third-quarter 2024 earnings on Oct. 22. The Zacks Consensus Estimate for net sales is pegged at $9.57 billion, suggesting an increase of 4.7% from the prior-year quarter’s reported figure. The consensus mark for third-quarter earnings has remained unchanged in the past 30 days at $1.83 per share, indicating a rise of 9.6% from the figure reported in the year-ago quarter. PM has a trailing four-quarter earnings surprise of 1.8%, on average.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Things to Consider About PM’s Upcoming Results
Philip Morris has been benefiting from its strong pricing power, which has aided its revenues and adjusted operating income even amid low cigarette volumes. Though higher pricing might lead to a possible decline in cigarette consumption, it is seen that smokers tend to absorb price increases owing to the addictive quality of cigarettes.
Philip Morris’ transition toward smoke-free alternatives has been working well, given consumers’ rising health consciousness and inclination toward reduced-risk products. Smoke-free products generated 38.1% of the company’s net revenues in the second quarter of 2024. In the quarter, the company witnessed continued strength in IQOS performance. Within the smoke-free business, inhalable smoke-free products were driven by strength in IQOS, while oral SFP was fueled by increased shipment volumes of ZYN. Strength in these products is likely to have aided in the quarter under review.
Philip Morris International Inc. Price, Consensus and EPS Surprise
High SG&A expenses are a concern for Philip Morris. With key commercial activities planned for the third quarter, SG&A expenses are expected to be high, posing a potential challenge. Apart from this, the company continues to encounter tobacco leaf inflation.
However, Philip Morris’ saving measures are likely to have offered respite, as it expects accelerated savings in the second half of the year. On its last earnings call, management stated that it expects to witness a robust second-half performance, which encouraged it to raise its full-year 2024 guidance despite the adverse currency movements. These upsides bode well for the third quarter.
Earnings Whispers for Philip Morris
Our proven model doesn’t conclusively predict an earnings beat for Philip Morris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
Philip Morris carries a Zacks Rank #2, while it has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are some companies worth considering, as our model shows that these have the correct combination to beat on earnings this time.
Clorox (CLX - Free Report) currently has an Earnings ESP of +2.41% and a Zacks Rank of 2. The company is likely to register top and bottom-line growth when it reports first-quarter fiscal 2025 numbers. The Zacks Consensus Estimate for Clorox’s quarterly revenues is pegged at $1.62 billion, which indicates an increase of 17.2% from the figure reported in the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Clorox’s quarterly earnings of $1.36 per share indicates growth of 177.6% from the year-ago quarter’s levels. CLX has a trailing four-quarter earnings surprise of 122.9%, on average.
Colgate-Palmolive (CL - Free Report) currently has an Earnings ESP of +0.96% and a Zacks Rank #3. The company is expected to register top and bottom-line growth when it reports third-quarter 2024 results. The Zacks Consensus Estimate for quarterly revenues is pegged at $5 billion, suggesting a rise of 1.9% from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for quarterly earnings has remained unchanged at 88 cents per share in the past 30 days. The consensus mark for CL’s earnings indicates growth of 2.3% from the year-ago quarter’s reported number. CL delivered an earnings surprise of 4.8%, on average, in the trailing four quarters.
Monster Beverage (MNST - Free Report) currently has an Earnings ESP of +0.13% and a Zacks Rank of 3. The company is expected to register top-and-bottom-line growth when it reports third-quarter 2024 results. Although the Zacks Consensus Estimate for MNST’s quarterly earnings has moved down by a penny in the past seven days to 42 cents per share, the projection indicates 2.4% growth from the year-ago quarter's reported number.
The Zacks Consensus Estimate for Monster Beverage’s quarterly revenues is pegged at $1.9 billion, suggesting a rise of 3.2% from the figure reported in the prior-year quarter. MNST reported a negative earnings surprise of 3.4%, on average, in the trailing four quarters.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Philip Morris' Q3 Earnings Coming Up: Here's What You Should Know
Philip Morris International Inc. (PM - Free Report) is likely to register top and bottom-line growth when it reports third-quarter 2024 earnings on Oct. 22. The Zacks Consensus Estimate for net sales is pegged at $9.57 billion, suggesting an increase of 4.7% from the prior-year quarter’s reported figure. The consensus mark for third-quarter earnings has remained unchanged in the past 30 days at $1.83 per share, indicating a rise of 9.6% from the figure reported in the year-ago quarter. PM has a trailing four-quarter earnings surprise of 1.8%, on average.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Things to Consider About PM’s Upcoming Results
Philip Morris has been benefiting from its strong pricing power, which has aided its revenues and adjusted operating income even amid low cigarette volumes. Though higher pricing might lead to a possible decline in cigarette consumption, it is seen that smokers tend to absorb price increases owing to the addictive quality of cigarettes.
Philip Morris’ transition toward smoke-free alternatives has been working well, given consumers’ rising health consciousness and inclination toward reduced-risk products. Smoke-free products generated 38.1% of the company’s net revenues in the second quarter of 2024. In the quarter, the company witnessed continued strength in IQOS performance. Within the smoke-free business, inhalable smoke-free products were driven by strength in IQOS, while oral SFP was fueled by increased shipment volumes of ZYN. Strength in these products is likely to have aided in the quarter under review.
Philip Morris International Inc. Price, Consensus and EPS Surprise
Philip Morris International Inc. price-consensus-eps-surprise-chart | Philip Morris International Inc. Quote
High SG&A expenses are a concern for Philip Morris. With key commercial activities planned for the third quarter, SG&A expenses are expected to be high, posing a potential challenge. Apart from this, the company continues to encounter tobacco leaf inflation.
However, Philip Morris’ saving measures are likely to have offered respite, as it expects accelerated savings in the second half of the year. On its last earnings call, management stated that it expects to witness a robust second-half performance, which encouraged it to raise its full-year 2024 guidance despite the adverse currency movements. These upsides bode well for the third quarter.
Earnings Whispers for Philip Morris
Our proven model doesn’t conclusively predict an earnings beat for Philip Morris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
Philip Morris carries a Zacks Rank #2, while it has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are some companies worth considering, as our model shows that these have the correct combination to beat on earnings this time.
Clorox (CLX - Free Report) currently has an Earnings ESP of +2.41% and a Zacks Rank of 2. The company is likely to register top and bottom-line growth when it reports first-quarter fiscal 2025 numbers. The Zacks Consensus Estimate for Clorox’s quarterly revenues is pegged at $1.62 billion, which indicates an increase of 17.2% from the figure reported in the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Clorox’s quarterly earnings of $1.36 per share indicates growth of 177.6% from the year-ago quarter’s levels. CLX has a trailing four-quarter earnings surprise of 122.9%, on average.
Colgate-Palmolive (CL - Free Report) currently has an Earnings ESP of +0.96% and a Zacks Rank #3. The company is expected to register top and bottom-line growth when it reports third-quarter 2024 results. The Zacks Consensus Estimate for quarterly revenues is pegged at $5 billion, suggesting a rise of 1.9% from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for quarterly earnings has remained unchanged at 88 cents per share in the past 30 days. The consensus mark for CL’s earnings indicates growth of 2.3% from the year-ago quarter’s reported number. CL delivered an earnings surprise of 4.8%, on average, in the trailing four quarters.
Monster Beverage (MNST - Free Report) currently has an Earnings ESP of +0.13% and a Zacks Rank of 3. The company is expected to register top-and-bottom-line growth when it reports third-quarter 2024 results. Although the Zacks Consensus Estimate for MNST’s quarterly earnings has moved down by a penny in the past seven days to 42 cents per share, the projection indicates 2.4% growth from the year-ago quarter's reported number.
The Zacks Consensus Estimate for Monster Beverage’s quarterly revenues is pegged at $1.9 billion, suggesting a rise of 3.2% from the figure reported in the prior-year quarter. MNST reported a negative earnings surprise of 3.4%, on average, in the trailing four quarters.